Premium
Camp chemotherapy for metastatic non‐oat cell bronchogenic carcinoma. A 7‐year experience (1975–1981) with 160 patients
Author(s) -
Shepard Kirk V.,
Golomb Harvey M.,
Bitran Jacob D.,
Hoffman Philip C.,
Newman Steven B.,
Demeester Tom R.,
Skosey Consuelo
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851115)56:10<2385::aid-cncr2820561007>3.0.co;2-o
Subject(s) - medicine , procarbazine , adenocarcinoma , chemotherapy , gastroenterology , carcinoma , regimen , cyclophosphamide , large cell , small cell carcinoma , oncology , vincristine , cancer
Between January 1975 and December 1981, 160 patients with metastatic non‐oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP), or with a CAMP‐like regimen. Forty‐two (26%) of these patients demonstrated an objective response to the chemotherapy with a median survival of 61 weeks. Thirty‐nine (24%) patients had stable disease (SD) with a median survival of 45 weeks. Seventy‐nine patients (49.4%) were nonresponders with a median survival of 15 weeks. There was a significant difference in survival times between the responders and the SD patients, and between the responders and SD patients and the nonresponders. Responses were seen in 11% of the patients with squamous cell carcinoma and in 37% of the patients with adenocarcinoma. There was a significant difference in the response and SD categories in favor of adenocarcinoma over squamous cell carcinoma. Once a response was achieved, the median survival of the patients with adenocarcinoma was not significantly longer than that of the patients with squamous cell carcinoma.